Evidence map›Paper›PMID 37124053›Full record

ArticleRespiratory medicine case reports2023

Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?

Toshiyuki Yonezawa, Atsushi Suzuki, Kensuke Fukumitsu, Takuma Katano, Hisashi Kako, Makoto Ishii, Akio Niimi, Kazuyoshi Imaizumi, Koji Sakamoto, Norihito Omote and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Acute exacerbation in fibrotic interstitial lung disease: an international working group report.American journal of respiratory and critical care medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Toshiyuki YonezawaDepartment of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Aichi, Japan.
Atsushi SuzukiDepartment of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan.
Kensuke FukumitsuDepartment of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan.
Takuma KatanoDepartment of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Aichi, Japan.
Hisashi KakoDepartment of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan.
Makoto IshiiDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Akio NiimiDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Kazuyoshi ImaizumiDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Koji SakamotoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Norihito OmoteDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Etsuro YamaguchiDepartment of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Aichi, Japan.
Nagoya University · JPAichi Medical University · JPFujita Health University · JPNagoya City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.

Indexed as

Acute exacerbationCOVID-19Interstitial lung diseasesRheumatoid arthritisTreatment

Identifiers

PMID37124053
PMCPMC10125217
OpenAlexW4366814485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.